報價延遲最少15分鐘:2026/11/04 14:31 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.8999 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.50/-0.50
|
|
企業價值
7.01M
|
| 資產負債 |
|
每股賬面淨值
0.96
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
7.71M
|
|
每股收益
0.15
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Immuron Ltd is a commercial- and clinical-stage biopharmaceutical company focused on the development and commercialization of specifically targeted polyclonal antibodies. Its oral polyclonal antibodies offer delivery within the GI tract and can target viruses or bacteria and neutralize toxins at mucosal surfaces. The Company markets Travelan in Australia, an over-the-counter orally administered passive immunotherapeutic product indicated to reduce the risk of traveler's diarrhea and minor gastrointestinal disorders. Its products include Travelan, ProIBS and Protectyn. Its segments are Research and Development and Hyper-immune products, with Hyper-immune products generating maximum revenue. Australia generatesmaximum revenue. |
